Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lerisetron SCHEMBL30669539 | 1.00 | HTR3A (1.00) | HTR3ASOS1 | |
| Lerisetron SCHEMBL29040939 | 0.99 | HTR3A (0.97) | HTR3ASOS1 | |
| SCHEMBL9023706 | 0.92 | HTR3A (0.85) | HTR3ASOS1 | |
| SCHEMBL7168715 | 0.90 | HTR3A (0.81) | HTR3A | |
| SCHEMBL7431298 | 0.90 | HTR3A (1.00) | HTR3ASOS1 | |
| SCHEMBL7386042 | 0.86 | HTR3A (0.75) | HTR3ASOS1 | |
| SCHEMBL7341277 | 0.86 | HTR3A (0.75) | HTR3A | |
| SCHEMBL7623108 | 0.85 | HTR3A (0.91) | HTR3ASOS1 | |
| SCHEMBL14498818 | 0.85 | HTR3A (0.73) | HTR3ASOS1 | |
| SCHEMBL7390282 | 0.85 | SOS1 (0.77) | HTR3ASOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1010 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| US-11547700-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2023-01-10 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3691637-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE Pharmaceuticals GmbH (AT) | 2020-08-12 | — | — | EP | claimed |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2020-08-06 | — | — | US | claimed |
| CN-111201019-A | Oral bendamustine formulations | 图贝药物有限公司 | 2020-05-26 | — | — | CN | claimed |
| US-20200121656-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA | CHASE PHARMACEUTICALS CORP (US) | 2020-04-23 | — | — | US | claimed |
| WO-2001074338-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE DELIVERY OF LERISETRON | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2001-10-11 | — | — | WO | claimed |
| US-6284770-B1 | ADMINISTERING SEROTONINE RECEPTOR ANTAGONIST | GLAXO WELLCOME INC. | 2001-09-04 | — | — | US | claimed |
| CN-1281357-A | Medicaments | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | claimed |
| US-6136807-A | MIXTURE WITH ACRYLATE POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-10-24 | — | — | US | claimed |
| EP-1021174-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | claimed |
| WO-2000027371-A1 | COMPOSITION FOR THE TRANSDERMAL DELIVERY OF LERISETRON | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-05-18 | — | — | WO | claimed |
| EP-0512939-B1 | 2-piperazinylbenzimidazole derivatives | ESPANOLA PROD QUIMICOS (ES) | 1999-08-25 | — | — | EP | claimed |
| WO-1999017755-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1999-04-15 | — | — | WO | claimed |
| US-5256665-A | Process for preparing new 2-piperazinylbenzimidazole | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1993-10-26 | — | — | US | claimed |
| EP-0512939-A1 | New 2-piperazinylbenzimidazole derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1992-11-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HTR3A 143/4885SOS1 788/4885 |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | ABCB1, MTHFD1, BHMT | HTR3A 3119/4885SOS1 2755/4885 |
| US-20200121656-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA | ACHE, BCHE, CHRNA3 | HTR3A 18/4885SOS1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.